Cell membrane vectors |
Red blood cell membrane |
Prolonged blood circulation; high biocompatibility; immune evasion |
Lack of specific targeting ligands on red blood cell membranes |
12,40,314 |
Cancer cell membrane |
Homotypic targeting capability; elicit specific immune response; easy to culture in vitro on a large scale |
Relatively short circulation time |
20,309 |
Immune cell membrane |
Targeting to the inflammatory site; immune evasion; elicit specific immune response |
The least component in the blood; only effective to certain tumors |
87–89 |
Hybrid cell membrane |
Multifunctional integration of individual cell types |
Lack of productive technique |
20 |
Evs vectors |
Exosome |
Tiny diameter; reduce phagocytosis; extravasate through tumor vessels; across biological barriers |
Limited to obtain high yields of pure Exo |
21 |
Microvesicle |
Inherit tumor-targeting capability |
More heterogeneous in size |
178 |
Viral vectors |
Mammalian viral nanoparticles |
Traditionally used in gene delivery strategies |
Causing horizontal genetic transfer events; stimulate undesirable immune responses |
315 |
Bacteriophage-viral nanoparticles |
Non-infectious to mammals; do not undergo alterations in their natural tropism or mutation; reduce side-effects and enhance bacterial targeting |
Problematic in the repeated application of a therapeutic cargo; rapidly cleaned by the host RES |
238,316 |
Plant virus-viral nanoparticles |
Non-infectious to mammals |
Do not exhibit tissue tropisms |
22 |